Evidence map›Paper›PMID 42584812›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026

Developing a medical-device formulary for council of health insurance beneficiaries in Saudi Arabia: stakeholder challenges and policy recommendations.

Shabab Alghamdi, Ibrahim Aljuffali, Nada Alagil, Amer Alanazi, Azzam Alothman, Wael Yar, Mohammed Aljumah, Saeed Mastour Alshahrani, Hadeel Alkofide

Abstract read
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shabab AlghamdiCouncil of Health Insurance, Riyadh, Saudi Arabia.
Ibrahim AljuffaliCouncil of Health Insurance, Riyadh, Saudi Arabia.
Nada AlagilMedical Department, Council of Health Insurance, Riyadh, Saudi Arabia. Nadaalgil33@gmail.com.ORCID http://orcid.org/0009-0004-0606-5304
Amer AlanaziDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Azzam AlothmanMedical Devices Surveillance Department, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
Wael YarHealth & Life Insurance - Prudential Supervision Insurance Authority, Riyadh, Saudi Arabia.
Mohammed AljumahItkan, Riyadh, Saudi Arabia.
Saeed Mastour AlshahraniDepartment of Public Health, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Hadeel AlkofideDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ensuring equitable access to dispensed-to-patient (DTP) medical devices is an important policy priority for health insurance systems. This mixed-method study examined stakeholder perspectives on barriers and policy priorities for developing a DTP medical-device formulary for health insurance beneficiaries in Saudi Arabia. An exploratory online survey was distributed to 58 purposively selected stakeholders, and 17 responded (29.3%). Survey findings were summarized descriptively as n/N (%) with 95% confidence intervals. A subsequent stakeholder consultation workshop with 42 stakeholders was used to explore survey themes and identify policy-relevant recommendations. Survey respondents identified several recurring barriers, including lack of standardized evaluation criteria for including new devices (15/17, 88.2%; 95% CI 65.7-96.7), lack of clarity on reimbursement policies (13/17, 76.5%; 95% CI 52.7-90.4), limited reimbursement coverage for certain devices (10/17, 58.8%; 95% CI 36.0-78.4), and fragmented coding and categorization systems. Qualitative findings highlighted the need for explicit eligibility criteria, transparent pricing, risk-based assessment pathways, and coding systems that support claims processing and post-market evidence generation. The findings support an evidence-informed, stakeholder-informed formulary process with clear governance, standardized assessment criteria, transparent reimbursement rules, and improved coding infrastructure. Given the small exploratory survey sample, the quantitative findings should be interpreted as preliminary and validated in larger stakeholder studies.

Indexed as

Formulary developmentHealth technology assessmentMedical devicesReimbursementSaudi ArabiaStakeholder perspectives

Identifiers

PMID42584812
PMCPMC13469036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.